
Opinion|Videos|August 28, 2024
Examining Trial Data on Omaveloxolone Efficacy
A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.
Advertisement
Episodes in this series

- In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
Long-term CR Seen With Allo-CAR-NK Cell Therapy Plus Rituximab in Waldenstrom NHL
3
France Expands BOT–BAL Immunotherapy Access for Ovarian Cancer and Soft Tissue Sarcoma
4
CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC
5






























































